دراسة فرامنغهام للقلب
الحواشي

↑  Thomas R. Dawber, M.D., Gilcin F. Meadors, M.D., M.P.H., and Felix E. Moore, Jr., National Heart Institute, National Institutes of Health, Public Health Service, Federal Security Agency, Washington, D. C., Epidemiological Approaches to Heart Disease: The Framingham Study Presented at a Joint Session of the Epidemiology, Health Officers, Medical Care, and Statistics Sections of the American Public Health Association, at the Seventy-eighth Annual Meeting in St. Louis, Mo., November 3, 1950.
↑  Richmond (2006). "Obituary: Thomas Royle Dawber". BMJ. ج. 332 ع. 7533: 122. DOI:10.1136/bmj.332.7533.122. مؤرشف من الأصل (fee required) في 2019-12-19.
↑  Some lessons in cardiovascular epidemiology from Framingham. Kannel WB. Am J Cardiol. 1976 Feb;37(2):269-82.
↑  Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham Heart Study. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, Massaro J, Silbershatz H, Wilson PW. Arch Intern Med. 2001 Apr 9;161(7):949-54.
↑  Homocysteine and heart failure: a review of investigations from the Framingham Heart Study. Sundström J, Vasan RS. Clin Chem Lab Med. 2005;43(10):987-92.
↑  Cardiovascular risk factors. Insights from Framingham Heart Study. O'Donnell CJ, Elosua R. Rev Esp Cardiol. 2008 Mar;61(3):299-310.
1 2  Genetics of the Framingham Heart Study population. Govindaraju DR, Cupples LA, Kannel WB, O'Donnell CJ, Atwood LD, D'Agostino RB Sr, Fox CS, Larson M, Levy D, Murabito J, Vasan RS, Splansky GL, Wolf PA, Benjamin EJ. Adv Genet. 2008;62:33-65.
↑  Nutritional research within the Framingham Heart Study. Millen BE, Quatromoni PA. J Nutr Health Aging. 2001;5(3):139-43.
↑  Women and cardiovascular disease: contributions from the Framingham Heart Study. Murabito JM. J Am Med Womens Assoc. 1995 Mar-Apr;50(2):35-9.
↑  The health risks of smoking. The Framingham Study: 34 years of follow-up. Freund KM, Belanger AJ, D'Agostino RB, Kannel WB. Ann Epidemiol. 1993 Jul;3(4):417-24.
↑  Mortality in relation to smoking: 50 years' observations on male British doctors. Doll R, Peto R, Boreham J, Sutherland I. BMJ. 2004 Jun 26;328(7455):1519.
↑  Brindle P؛ Emberson J؛ Lampe F؛ وآخرون (2003). "Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study". BMJ. ج. 327 ع. 7426: 1267. DOI:10.1136/bmj.327.7426.1267. PMC:286248. PMID:14644971. {{استشهاد بدورية محكمة}}: الوسيط غير المعروف |author-separator= تم تجاهله (مساعدة)
↑  David Hadden (2002). "Holidays in Framingham?". BMJ. ج. 325 ع. 7363: 544. DOI:10.1136/bmj.325.7363.544. مؤرشف من الأصل في 2006-02-16. {{استشهاد بدورية محكمة}}: الوسيط غير المعروف |شهر= تم تجاهله يقترح استخدام |تاريخ= (مساعدة)
↑  Christakis Nicholas A.؛ Fowler James H. (2007). "The Spread of Obesity in a Large Social Network Over 32 Years". New England Journal of Medicine. ج. 357 ع. 4: 370–379. DOI:10.1056/NEJMsa066082. PMID:17652652.
↑  "Research Milestones Framingham Heart Study". مؤرشف من الأصل في 2013-11-06.
↑  "About the Boston University School of Medicine". مؤرشف من الأصل في 17 أغسطس 2012. اطلع عليه بتاريخ أغسطس 2020. {{استشهاد ويب}}: تحقق من التاريخ في: |تاريخ الوصول= (مساعدة)
↑  Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, Levy D, Murabito JM, Wang TJ, Wilson PW, O'Donnell CJ. JAMA. 2004 May 12;291(18):2204-11.
↑  Genetic variation in white matter hyperintensity volume in the Framingham Study. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, DeCarli C. Stroke. 2004 Jul;35(7):1609-13.
↑  Homocysteine and cognitive performance in the Framingham offspring study: age is important. Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Jacques PF, Selhub J, Seshadri S, Au R, Beiser A, Wolf PA. Am J Epidemiol. 2005 Oct 1;162(7):644-53.
↑  A common genetic variant is associated with adult and childhood obesity. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, Wichmann HE, Meitinger T, Hunter D, Hu FB, Colditz G, Hinney A, Hebebrand J, Koberwitz K, Zhu X, Cooper R, Ardlie K, Lyon H, Hirschhorn JN, Laird NM, Lenburg ME, Lange C, Christman MF. Science. 2006 Apr 14;312(5771):279-83.
↑  Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hazra A, Kraft P, Lazarus R, Chen C, Chanock SJ, Jacques P, Selhub J, Hunter DJ. Hum Mol Genet. 2009 Dec 1;18(23):4677-87.
↑  The Framingham Heart Study, on its way to becoming the gold standard for Cardiovascular Genetic Epidemiology? Jaquish CE. BMC Med Genet. 2007 Oct 4;8:63.
↑  Overview of the risk factors for cardiovascular disease. Wilson PWF. In: UpToDate [Textbook of Medicine]. Basow DS (Ed). Massachusetts Medical Society, and Wolters Kluwer publishers. 2010.
↑  A list of publications from the Busselton study نسخة محفوظة 24 أكتوبر 2009 على موقع واي باك مشين.
↑  Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. Knuiman MW, Vu HT. J Epidemiol Community Health. 1997 Oct;51(5):515-9.
↑  Is sleep apnea an independent risk factor for prevalent and incident diabetes in the Busselton Health Study? Marshall NS, Wong KK, Phillips CL, Liu PY, Knuiman MW, Grunstein RR. J Clin Sleep Med. 2009 Feb 15;5(1):15-20.
↑  China Study II, Cornell University.نسخة محفوظة 15 يناير 2013 على موقع واي باك مشين.
في كومنز مواد ذات صلة بـ دراسة فرامنغهام للقلب.
بوابة الولايات المتحدة
بوابة طب
بوابة إحصاء
| 0 | 1 |
| --- | --- |
ضبط استنادي :  الاسم المعياري الدولي (ISNI)